

**DESCRIPTION**



<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human GPR158 in direct ELISAs.
<b>Source</b>	Monoclonal Mouse IgG <sub>2B</sub> Clone # 1027651
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Human embryonic kidney cell HEK293-derived human GPR158 protein Ala24-Gln411 Accession # Q5T848
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Flow Cytometry</b>	0.25 µg/10 <sup>6</sup> cells	HEK293 Human Cell Line Transfected with Human GPR158 and eGFP
<b>Immunocytochemistry</b>	8-25 µg/mL	Immersion fixed T47D human breast cancer cell line

**DATA**

<p><b>Flow Cytometry</b></p>  <p><b>Detection of GPR158 in HEK293 Human Cell Line Transfected with Human GPR158 and eGFP by Flow Cytometry.</b> HEK293 human embryonic kidney cell line transfected with (A) human GPR158 or (B) irrelevant protein, and eGFP was stained with Mouse Anti-Human GPR158 Monoclonal Antibody (Catalog # MAB102861) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB0041). Staining was performed using our Staining Membrane-associated Proteins protocol.</p>	<p><b>Immunocytochemistry</b></p>  <p><b>GPR158 in T47D Human Cell Line.</b> GPR158 was detected in immersion fixed T47D human breast cancer cell line using Mouse Anti-Human GPR158 Monoclonal Antibody (Catalog # MAB102861) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell membrane. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells.</p>
--	---

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

G-protein coupled receptor 158 (GPR158) is a receptor belonging to the Class C GPCR family. It lacks the extracellular Venus flytrap module characteristic of the known members of that family and instead contains two other elements that are not typical of the class: a calcium-binding EGF-like domain and a leucine repeat region (1, 2). The mature extracellular domain of human GPR158 contains 393 amino acids (aa) and shares 89% identity with both mouse and rat GPR158. GPR158 is expressed at the highest level in the brain, but also in a variety of other tissues including retina, spleen, liver and lung (3). GPR158 was originally identified in functional screens linked with biological stress and has been implicated in the osteocalcin effect on cognitive processes in the brain (4, 5), and glaucoma and cancer in the periphery (4, 6).

**References:**

1. Jingami, H. *et al.* (2003) *Curr. Opin. Neurobiol.* **13**:271.
2. Bjarnadóttir, T.K *et al.* (2005) *Gene.* **362**:70.
3. Orlandi, C. *et al.* (2012) *J. Cell Biol.* **197**:711.
4. Itakura, T. *et al.* (2019) *J. Ocul. Pharmacol. Ther.* **35**:203.
5. Khramian, L. *et al.* (2017) *J. Exp. Med.* **214**:2859.
6. Fenner, A. (2015) *Nat. Rev. Urol.* **12**:182.